Lion Biotechnologies, Inc. (NASDAQ:IOVA) has been given a $13.00 target price by stock analysts at Oppenheimer Holdings, Inc. in a report released on Tuesday. The firm currently has a “buy” rating on the biotechnology company’s stock. Oppenheimer Holdings, Inc.’s target price indicates a potential upside of 67.20% from the stock’s current price.

Several other research firms also recently issued reports on IOVA. Zacks Investment Research upgraded shares of Lion Biotechnologies from a “hold” rating to a “buy” rating and set a $8.25 price objective for the company in a research note on Tuesday, October 17th. HC Wainwright set a $16.00 target price on shares of Lion Biotechnologies and gave the company a “buy” rating in a research note on Monday. Jefferies Group LLC restated a “buy” rating on shares of Lion Biotechnologies in a research note on Sunday. Chardan Capital restated a “buy” rating on shares of Lion Biotechnologies in a research note on Thursday, September 7th. Finally, FBR & Co restated a “buy” rating and issued a $17.50 target price on shares of Lion Biotechnologies in a research note on Wednesday, October 25th. Ten research analysts have rated the stock with a buy rating, The stock currently has a consensus rating of “Buy” and an average target price of $14.09.

Shares of Lion Biotechnologies (IOVA) opened at 7.775 on Tuesday. Lion Biotechnologies has a 12-month low of $4.45 and a 12-month high of $8.60. The firm’s market capitalization is $556.12 million. The firm’s 50-day moving average is $7.55 and its 200-day moving average is $6.51.

WARNING: This report was originally posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this report on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright law. The original version of this report can be viewed at https://theolympiareport.com/2017/11/01/lion-biotechnologies-inc-iova-given-a-13-00-price-target-by-oppenheimer-holdings-inc-analysts.html.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Victory Capital Management Inc. raised its holdings in shares of Lion Biotechnologies by 2.0% during the third quarter. Victory Capital Management Inc. now owns 2,638,323 shares of the biotechnology company’s stock worth $20,447,000 after purchasing an additional 51,450 shares during the period. Edge Wealth Management LLC bought a new position in shares of Lion Biotechnologies during the third quarter worth about $150,000. Sabby Management LLC bought a new position in shares of Lion Biotechnologies during the second quarter worth about $524,000. Broadfin Capital LLC bought a new position in shares of Lion Biotechnologies during the second quarter worth about $16,731,000. Finally, California State Teachers Retirement System bought a new position in shares of Lion Biotechnologies during the second quarter worth about $688,000. 66.57% of the stock is currently owned by hedge funds and other institutional investors.

Lion Biotechnologies Company Profile

Iovance Biotherapeutics, Inc, formerly Lion Biotechnologies, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company’s lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients’ tumors, for the treatment of metastatic melanoma.

Analyst Recommendations for Lion Biotechnologies (NASDAQ:IOVA)

Receive News & Ratings for Lion Biotechnologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lion Biotechnologies Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.